In addition, the CBM complex component CARD11 appeared to be highly expressed in sensitive MCL lines, suggesting that BCR pathway components can be deregulated to treat cells that are sensitive to inhibition of the canonical NF-κB pathway [49]. Here, BCR is linked to mantle cell lymphoma.